# A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)

> **NCT01462292** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 51 (actual)

## Conditions studied

- Muscular Dystrophies

## Interventions

- **DRUG:** GSK2402968 3mg/kg/week
- **DRUG:** GSK2402968 6 mg/kg/week
- **DRUG:** Placebo to match GSK2402968 3 mg/kg/week
- **DRUG:** Placebo to match GSK2402968 6 mg/kg/week

## Key facts

- **NCT ID:** NCT01462292
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-26
- **Primary completion:** 2013-05-21
- **Final completion:** 2013-11-04
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2017-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01462292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01462292, "A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01462292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*